Hradsky Ondrej, Soucek Ondrej, Maratova Klara, Matyskova Jana, Copova Ivana, Zarubova Kristyna, Bronsky Jiri, Sumnik Zdenek
Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Inflamm Bowel Dis. 2017 Apr;23(4):514-523. doi: 10.1097/MIB.0000000000001047.
Inflammatory bowel diseases (IBD) are associated with altered bone health and increased risk for fractures. Vitamin D deficiency is frequently found in IBD; however, the effect of vitamin D supplementation on bone health of children with IBD is poorly understood. We aimed to observe the changes in volumetric bone density and dynamic muscle functions after vitamin D substitution in a cohort of pediatric patients with IBD.
This was a prospective observational study of 55 patients (aged 5-19 years) with IBD. Bone quality was assessed using peripheral quantitative computed tomography and muscle functions by jumping mechanography at baseline and after a median of 13.8 (interquartile range, 12.0-16.0) months of daily substitution of 2000 IU of cholecalciferol.
Median serum levels of 25-hydroxyvitamin D increased from 58 nmol/L at the baseline visit to 85 nmol/L at the last follow-up visit (P < 0.001); no signs of overdose were reported. The Z-scores of trabecular bone mineral density, cortical bone cross-sectional area, and maximal muscle power improved significantly during the follow-up period (+0.5, P = 0.001, +0.3, P = 0.002 and +0.5, P = 0.002, respectively). Cholecalciferol substitution was positively associated with trabecular bone mineral density and maximal muscle power (estimates 0.26, 95% confidence interval 0.14-0.37, P < 0.0001 and 0.60, 95% confidence interval 0.32-0.85, P < 0.0001, respectively) but not with the Strength-Strain Index or maximal muscle force (Fmax).
We observed an improvement in bone and muscle parameters after cholecalciferol substitution in pediatric patients with IBD. Therefore, vitamin D substitution can be considered in such patients.
炎症性肠病(IBD)与骨骼健康改变及骨折风险增加有关。IBD患者中经常发现维生素D缺乏;然而,维生素D补充剂对IBD患儿骨骼健康的影响尚不清楚。我们旨在观察一组IBD儿科患者补充维生素D后骨体积密度和动态肌肉功能的变化。
这是一项对55例年龄在5至19岁的IBD患者进行的前瞻性观察研究。在基线时以及每日补充2000 IU胆钙化醇中位数为13.8(四分位间距,12.0 - 16.0)个月后,使用外周定量计算机断层扫描评估骨质量,并通过跳跃力学测定法评估肌肉功能。
25 - 羟基维生素D的血清中位数水平从基线访视时的58 nmol/L增加到最后一次随访时的85 nmol/L(P < 0.001);未报告过量迹象。在随访期间,小梁骨矿物质密度、皮质骨横截面积和最大肌肉力量的Z值显著改善(分别为+0.5,P = 0.001;+0.3,P = 0.002;+0.5,P = 0.002)。胆钙化醇替代与小梁骨矿物质密度和最大肌肉力量呈正相关(估计值分别为0.26,95%置信区间0.14 - 0.37,P < 0.0001和0.60,95%置信区间0.32 - 0.85,P < 0.0001),但与强度 - 应变指数或最大肌肉力量(Fmax)无关。
我们观察到IBD儿科患者补充胆钙化醇后骨骼和肌肉参数有所改善。因此,此类患者可考虑补充维生素D。